Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Beverly Mauger

Nurse Practitioner, Family Ft Wayne, IN Nurse Practitioner

NPI 1548529084 CMS profile 10997829

6326 Constitution Dr, Ft Wayne, IN 46804

Open in the dashboard

General payments

$93,723

140 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Beverly Mauger of Ft Wayne, IN is reported in the CMS Open Payments database as having received $93,723 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $92,852 123
2023 General $201 2
2022 General $389 7
2021 General $281 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Beverly Mauger
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Beverly Mauger were reported at $92,852. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Beverly Mauger Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $281 $124 $35–$379 $132
2022 $389 $141 $44–$430 $149
2023 $201 $154 $49–$476 $160
2024 $0 $165 $51–$504 $164
2025 $92,852 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $92,248 101 payments
  2. ACADIA Pharmaceuticals Inc $526 12 payments
  3. Teva Pharmaceuticals USA, Inc. $431 6 payments
  4. Otsuka America Pharmaceutical, Inc. $273 8 payments
  5. E.R. Squibb & Sons, L.L.C. $200 10 payments
  6. Avanir Pharmaceuticals, Inc. $27 2 payments
  7. Alkermes, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $75,944 27 payments
  2. Travel and Lodging $7,391 47 payments
  3. Consulting Fee $6,750 1 payment
  4. Food and Beverage $3,465 61 payments
  5. Education $173 4 payments
Products named General payments · program years 2021–2025
  1. INGREZZA Neuropsychiatry $92,123 100 payments
  2. NUPLAZID Parkinsons Disease Psychosis $397 7 payments
  3. REXULTI $273 8 payments
  4. COBENFY $154 6 payments
  5. AUSTEDO $139 2 payments
  6. INGREZZA Neurology $125 1 payment
  7. Austedo XR $124 1 payment
  8. NUPLAZID Pdp $114 1 payment
  9. NUEDEXTA $27 2 payments
  10. LYBALVI $17 1 payment
  11. Other $84 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

10,576

Median for Nurse Practitioner: 389

Drug cost

$1,652,432

Median for Nurse Practitioner: $21,885

Branded share of claims

13%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 121 $506,831
Invega Sustenna Paliperidone Palmitate Brand 142 $494,109
Rexulti Brexpiprazole Brand 147 $108,920
Abilify Maintena Aripiprazole Brand 34 $100,959
Eliquis Apixaban Brand 70 $38,946
Risperidone Er Risperidone Microspheres Brand 37 $29,654
Risperdal Consta Risperidone Microspheres Brand 19 $22,162
Nuedexta Dextromethorphan Hbr/Quinidine Brand 32 $21,185
Buspirone Hcl Generic 995 $20,097
Aripiprazole Generic 199 $15,963

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$188,865

Medicare's payments for the services billed

Medicare patients

842

Average age 76

Services billed

3,540

500 women, 342 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 71%
Alzheimer's or dementia 56%
Arthritis 49%
Diabetes 45%
Chronic kidney disease 40%
COPD 38%
Heart failure 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record